These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9579378)

  • 21. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wrist Deformity in Children and Adolescents with b-thalassemia on Oral Iron Chelation Therapy.
    Merchant RH; Kulkarni A; Doctor PN; Choudhari A; Patkar DP
    Indian Pediatr; 2019 Jan; 56(1):41-44. PubMed ID: 30806360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251-264].
    Nick HP
    Hemoglobin; 2011; 35(2):175-9. PubMed ID: 21417578
    [No Abstract]   [Full Text] [Related]  

  • 26. Current status of iron overload and chelation with deferasirox.
    Choudhry VP; Naithani R
    Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption.
    Mehdizadeh M; Nowroozzadeh MH
    Clin Exp Optom; 2009 Jul; 92(4):392-4. PubMed ID: 19515094
    [No Abstract]   [Full Text] [Related]  

  • 28. Deferasirox Novartis.
    Barton JC
    Curr Opin Investig Drugs; 2005 Mar; 6(3):327-35. PubMed ID: 15816510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lactose intolerance is not the cause of gastrointestinal adverse effects in beta thalassemia patients treated with deferasirox.
    Pazgal I; Brown M; Perets TT; Niv Y; Rachmilewitz E; Stark P
    Am J Hematol; 2014 Sep; 89(9):938-9. PubMed ID: 24923845
    [No Abstract]   [Full Text] [Related]  

  • 30. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V; Bourantas D; Chaidos A; Bouranta P; Gouva M; Vassou A; Tzouvara E; Bourantas KL
    Hematol J; 2004; 5(6):475-9. PubMed ID: 15570288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron chelation with oral deferiprone in patients with thalassemia.
    Tricta F; Spino M
    N Engl J Med; 1998 Dec; 339(23):1710; author reply 1713-4. PubMed ID: 9867536
    [No Abstract]   [Full Text] [Related]  

  • 32. Iron chelation therapy.
    Hershko CM; Link GM; Konijn AM; Cabantchik ZI
    Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
    Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compliance with iron chelation therapy in beta thalassaemia.
    Vidler V
    Paediatr Nurs; 1998 Oct; 10(8):17-8, 20. PubMed ID: 10095669
    [No Abstract]   [Full Text] [Related]  

  • 35. Iron chelation with oral deferiprone in patients with thalassemia.
    Nathan DG; Weatherall DJ
    N Engl J Med; 1998 Dec; 339(23):1711-2; author reply 1713-4. PubMed ID: 9867538
    [No Abstract]   [Full Text] [Related]  

  • 36. Beta-thalassaemia: emergence of new and improved iron chelators for treatment.
    Wong C; Richardson DR
    Int J Biochem Cell Biol; 2003 Jul; 35(7):1144-9. PubMed ID: 12672484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron chelation with oral deferiprone in patients with thalassemia.
    Stella M; Pinzello G; Maggio A
    N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867539
    [No Abstract]   [Full Text] [Related]  

  • 38. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ; Weatherall DJ
    Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
    [No Abstract]   [Full Text] [Related]  

  • 39. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.
    Ford JM; Rojkjaer L
    Haematologica; 2008 Jun; 93(6):e49; discussion e50. PubMed ID: 18515872
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.